Topic: Rsv Vaccine

CBS News reports on the new Vaccine Advisory Committee's focus on the risks of the childhood vaccination schedule. The segment features a pediatrician defending the benefits of the RSV immunization for infants. The hosts criticize the news presentation for functioning as an "ad for the RSV vaccine" and discuss the history of thimerosal and the 1976 swine flu vaccine issues.

The BBC reports on the development of mRNA vaccines for Norovirus, traditionally known as the "24-hour bug." The hosts discuss the symptoms of the virus, including intense gastrointestinal distress, and note its recent branding as a major public health threat. Vaccination rates for the flu and COVID-19 are reportedly lower than desired, leading to increased media pressure for uptake.

Moderna abruptly halted its mRNA vaccine clinical trial for Respiratory Syncytial Virus (RSV) in children after data indicated the vaccine might worsen the disease. The FDA disclosed that vaccinated children in the trial experienced severe RSV at rates up to three times higher than the placebo group.

The sudden prominence of RSV in public health messaging is linked to the development of new vaccines for the virus. The hosts revisit a 1960s study where an RSV vaccine caused enhanced respiratory disease in children, expressing skepticism about current mRNA-based treatments.

A new Pfizer promotional campaign features a grandmother sharing her experience with RSV (Respiratory Syncytial Virus) to encourage vaccination among seniors. The ad emphasizes the risk of grandparents catching the virus from their grandchildren, a marketing tactic criticized as fear-based.

New CDC Director Dr. Mandy Cohen appeared on the Today show to urge Americans to get updated COVID-19, flu, and RSV vaccinations before holiday gatherings. The hosts criticize her "marketing" approach and the agency's attempt to rebuild trust through transparency. The segment highlights the continued push for vaccines despite public fatigue and skepticism regarding their effectiveness in stopping transmission.

A "boots on the ground" report from a physician in the Netherlands describes a Pfizer-sponsored lunch aimed at raising awareness for RSV vaccines. The report notes that while RSV is common in infants, it is rarely a cause for hospitalization in the elderly, yet it is being marketed to seniors to "gouge" government healthcare systems. The hosts discuss the financial incentives for doctors to push unnecessary shots to Medicare recipients.

CDC Director Dr. Mandy Cohen issues a holiday message urging Americans to get updated COVID-19, flu, and RSV vaccines before Thanksgiving. The hosts compare the "updated" vaccine marketing to software updates for Windows or iPhones. They also play an older clip of Keith Olbermann aggressively criticizing those who are "vaccine hesitant."

Pfizer CEO Albert Bourla appeared on CNBC's "Mad Money" to discuss the company's earnings. He attributed lower COVID-19 vaccine uptake to "vaccine fatigue" and "anti-vaxxer rhetoric," while Jim Cramer expressed confusion over why more people are not following his lead in getting boosted.

"Boots on the ground" reports from medical professionals suggest the widely reported shortage of RSV vaccines is a manufactured narrative to drive demand. Doctors indicate that insurance companies are refusing to cover the $1,000 shots because the risk to healthy adults is statistically negligible. The conflict appears to be a financial dispute between pharmaceutical manufacturers and insurers.

Top executive producers were recognized for their financial support, including Sir Animus of Dogpatch, who reported receiving "SSSS" designations on his airline tickets due to his association with the show. Other donors discussed local issues, such as the aggressive marketing of RSV vaccines to the elderly and the legal implications of the Georgia RICO case. The segment emphasized the diverse professional and economic backgrounds of the "Gitmo Nation" producers.

Public health messaging has shifted to include RSV as a primary concern for adults over 60, despite it historically being known as a childhood respiratory illness. Observations of wastewater data suggest RSV levels are flatlined in most of the country, leading to claims that the pharmaceutical industry is manufacturing demand for a new vaccine category. The synchronized media push for "three shots by Halloween" is identified as a coordinated marketing script.

Robert F. Kennedy Jr. pledged to sign a treaty ending all gain-of-function research, claiming it has provided no benefits and may be responsible for various disease outbreaks. He suggests that several major illnesses, including RSV and potentially the Spanish flu, originated in vaccine research laboratories. Kennedy cites the book "The River" to support theories regarding the laboratory origins of HIV and Ebola.

A correction is issued regarding the safety data of new RSV vaccines. The hosts highlight reports indicating that the vaccines may be associated with increased rates of preterm births and neonatal deaths, rather than just efficacy concerns.

An FDA advisory panel voted 14-0 to recommend Pfizer’s maternal RSV vaccine, though the safety vote was a narrower 10-4 due to concerns over preterm births. Competitor GlaxoSmithKline previously paused its own RSV vaccine trials following "significant safety signals," including neonatal deaths. The vaccine is intended for administration to pregnant women to protect infants for their first six months of life.

Pfizer is seeking FDA approval for an RSV vaccine to be administered to pregnant women to transfer antibodies to their fetuses. Pfizer CEO Albert Bourla characterized the growing skepticism toward vaccines as an "assault on science" and "politicization" of health. The hosts question the sudden emergence of "RSV season" as a marketing concept and express concern over the safety of mRNA technology in maternal care.

Pfizer announced that its new RSV vaccine, administered to pregnant women in their late second or third trimester, showed 82% effectiveness in protecting newborns from severe illness. The company plans to submit the vaccine for FDA approval by the end of the year. The hosts express skepticism regarding the timing of the vaccine's release and the safety of maternal immunization.

Reports from Australia describe a "COVID variant soup" of mutations, while Montreal Children's Hospital reports ER capacity exceeding 250%. Despite claims of unprecedented overcrowding, video footage from some hospitals shows empty waiting rooms. The hosts suggest that the perceived crisis is driven by a shortage of healthcare staff resulting from vaccine mandates rather than an overwhelming number of patients.

Anthony Fauci proposed a "rebound effect" theory to explain the sudden rise in RSV and flu, suggesting these viruses were "bumped off the table" by COVID-19 for two years. Some analysts speculate the aggressive push for mRNA vaccines is a CIA-led effort to establish a rapid-response platform for future bioweapon attacks. This theory suggests the current vaccination drive serves as a "tranche" to identify and remove those genetically susceptible to mRNA toxicity.

Pfizer announced plans to increase the price of its COVID-19 vaccine to approximately $120 per dose once federal government purchasing ends. This coincides with the emergence of a "tripledemic," a term used by the New York Times to describe the simultaneous rise of COVID-19, the flu, and RSV. Hospitals in 43 states are reportedly facing a surge in respiratory illnesses, particularly among children under five.